PubRank

Brian Claggett

Author PubWeight™ 39.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014 7.48
2 Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015 4.56
3 The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015 3.36
4 Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med 2013 3.09
5 Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities). JACC Heart Fail 2013 1.51
6 Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015 1.49
7 Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. Eur J Heart Fail 2014 1.44
8 EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY. J Am Stat Assoc 2013 1.33
9 Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. Gastrointest Endosc 2011 1.06
10 Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail 2014 0.96
11 Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012 0.91
12 Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association. PLoS One 2013 0.91
13 Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. Clin Transl Gastroenterol 2012 0.90
14 Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 2014 0.90
15 Moving beyond our comfort zone. Eur Heart J 2013 0.90
16 Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med 2015 0.89
17 Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2013 0.89
18 Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail 2014 0.87
19 Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail 2013 0.84
20 Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc 2013 0.81
21 Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2015 0.81
22 Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study. Hypertension 2013 0.80
23 Analytical issues regarding rosiglitazone meta-analysis. Arch Intern Med 2011 0.77
24 Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? J Am Coll Cardiol 2014 0.75
25 Reply from the authors. Am J Respir Crit Care Med 2014 0.75
26 Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. J Hypertens 2014 0.75
27 Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2016 0.75
28 Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”. Circ Heart Fail 2015 0.75
29 A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016 0.75